DK1542528T3 - Fremgangsmåde til behandling og profylakse - Google Patents

Fremgangsmåde til behandling og profylakse

Info

Publication number
DK1542528T3
DK1542528T3 DK03792044.4T DK03792044T DK1542528T3 DK 1542528 T3 DK1542528 T3 DK 1542528T3 DK 03792044 T DK03792044 T DK 03792044T DK 1542528 T3 DK1542528 T3 DK 1542528T3
Authority
DK
Denmark
Prior art keywords
inflammatory
prophylaxis
treatment
present
further provides
Prior art date
Application number
DK03792044.4T
Other languages
Danish (da)
English (en)
Inventor
Kathryn Elizabeth Lawlor
Ian Peter Wicks
Ian Keith Campbell
Andrew Warwick Roberts
Donald Metcalf
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002950957A external-priority patent/AU2002950957A0/en
Priority claimed from AU2002951071A external-priority patent/AU2002951071A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of DK1542528T3 publication Critical patent/DK1542528T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK03792044.4T 2002-08-23 2003-08-22 Fremgangsmåde til behandling og profylakse DK1542528T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002950957A AU2002950957A0 (en) 2002-08-23 2002-08-23 A method of treatment and prophylaxis
AU2002951071A AU2002951071A0 (en) 2002-08-29 2002-08-29 A method of treatment and prophylaxis - II
PCT/AU2003/001078 WO2004017727A1 (en) 2002-08-23 2003-08-22 A method of treatment and prophylaxis

Publications (1)

Publication Number Publication Date
DK1542528T3 true DK1542528T3 (da) 2010-02-01

Family

ID=31947212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792044.4T DK1542528T3 (da) 2002-08-23 2003-08-22 Fremgangsmåde til behandling og profylakse

Country Status (12)

Country Link
US (1) US20060093604A1 (enExample)
EP (1) EP1542528B1 (enExample)
JP (1) JP4611738B2 (enExample)
AT (1) ATE443763T1 (enExample)
CA (1) CA2496485C (enExample)
DE (1) DE60329402D1 (enExample)
DK (1) DK1542528T3 (enExample)
ES (1) ES2333595T3 (enExample)
IL (1) IL167060A (enExample)
NZ (1) NZ538421A (enExample)
WO (1) WO2004017727A1 (enExample)
ZA (1) ZA200501629B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2506065T3 (es) 2006-08-11 2014-10-13 Csl Limited Tratamiento de estados patológicos pulmonares
US9364534B2 (en) * 2009-09-15 2016-06-14 Csl Limited Treatment of neurological conditions
US20110117092A1 (en) * 2009-10-20 2011-05-19 The Regents Of The University Of Michigan Compositions and methods for inhibiting g-csfr
WO2018145206A1 (en) 2017-02-07 2018-08-16 Me Therapeutics Inc. Anti-g-csf antibodies and uses thereof
CN114755165B (zh) * 2022-04-21 2024-11-22 重庆医科大学附属第二医院 一种用于检测g-csfr的流式检测试剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5902584A (en) * 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
AUPM375194A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US6716811B1 (en) * 2000-07-20 2004-04-06 Affymax, Inc. Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
MXPA03002045A (es) * 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.

Also Published As

Publication number Publication date
CA2496485A1 (en) 2004-03-04
ATE443763T1 (de) 2009-10-15
ZA200501629B (en) 2014-03-26
NZ538421A (en) 2008-08-29
DE60329402D1 (de) 2009-11-05
JP4611738B2 (ja) 2011-01-12
JP2005536535A (ja) 2005-12-02
CA2496485C (en) 2014-07-15
IL167060A (en) 2011-08-31
EP1542528B1 (en) 2009-09-23
US20060093604A1 (en) 2006-05-04
EP1542528A4 (en) 2005-12-28
EP1542528A1 (en) 2005-06-22
WO2004017727A1 (en) 2004-03-04
ES2333595T3 (es) 2010-02-24

Similar Documents

Publication Publication Date Title
AU2003263552A8 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
TW200501976A (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
IS2882B (is) Samsetning epóþílonhliðstæðna og virkra efna til efnameðferðar til þess að meðhöndla frumufjölgunarsjúkdóma
ATE451104T1 (de) Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
GB0209891D0 (en) Novel compounds
HUP9702036A1 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
HUP9702035A2 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek, valamint e vegyületeket tartalmazó gyógyászati készítmények
NO20061194L (no) Mitotiske kinesininbibitorer
HUP9702034A2 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
TW200510311A (en) CCr8 inhibitors
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DK1542528T3 (da) Fremgangsmåde til behandling og profylakse
DE60329326D1 (de) Tace inhibitoren
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.